Table 3.

Number of participants with a clinically relevant change (≥4 points compared with baseline) in GSS score during the whole 14‐d period in the four treatment arms (median ± semi‐interquartile range)

GSS Item	60/20	90/30	120/40	Conv. orlistat
(1) How often have you been to the toilet for defecation?	0 ± 0*	0 ± 1*	2 ± 1	2 ± 1
(2) Have you had oily stools? [≥3 points compared with baseline]	2 ± 1*	2 ± 2*	5 ± 1	5 ± 2
(3) How often have you had liquid stools?	1 ± 1*	0 ± 1*	2 ± 1	3 ± 1
(4) How often have you had flatulence with discharge?	0 ± 1*	0 ± 0*	3 ± 1*	1 ± 1
(5) How often have you had oily spotting?	0 ± 0*	0 ± 0*	1 ± 1*	2 ± 1
(6) How often have you had faecal urgency?	0 ± 0*	0 ± 0*	1 ± 0	1 ± 0
(7) How often have you had faecal incontinence?	0 ± 0*	0 ± 0*	0 ± 0*	1 ± 0
(8) Have you experienced nausea?	0 ± 0	0 ± 0	0 ± 0	0 ± 0
(9) Have you experienced rectal pain?	0 ± 0	0 ± 0	0 ± 0	0 ± 0
(10) Have you experienced headache?	2 ± 1	1 ± 0	3 ± 1*	2 ± 1
(11) Have you experienced gastric distention?	1 ± 1	3 ± 1*	3 ± 1*	0 ± 1
(12) Have you experienced gastrointestinal pain/discomfort	1 ± 1	0 ± 1*	2 ± 1	1 ± 1
(13) Have you experienced flatulence?	4 ± 1	6 ± 1*	7 ± 1*	2 ± 1

Abbreviation: GSS: gastric symptom score.

^* P<.05 for being different from conventional orlistat (adjusted for multiple comparisons).